Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORGN001 in Pediatric MoCD Type A
NCT02629393Phase 3Completed
- Sponsor
- Origin Biosciences
- Start
- May 2016
- Primary completion
- Sep 2022
- Modality
- Recombinant Proteins and Enzymes, Metabolically Activated Prodrugs
- Countries
- 6
01
Overview
A Phase 3 trial of fosdenopterin in molybdenum cofactor deficiency type A (MoCD-A), sponsored by Origin Biosciences. Started May 2016; status: completed.
02
Drugs
fosdenopterin
03
Conditions
molybdenum cofactor deficiency type A (MoCD-A)
Beyond the preview
Go deeper on NCT02629393.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02629393.